SG Americas Securities LLC Reduces Holdings in uniQure N.V. $QURE

SG Americas Securities LLC reduced its position in uniQure N.V. (NASDAQ:QURE) by 88.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 10,579 shares of the biotechnology company’s stock after selling 84,180 shares during the period. SG Americas Securities LLC’s holdings in uniQure were worth $617,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of QURE. Private Trust Co. NA acquired a new position in shares of uniQure in the third quarter worth about $28,000. Main Management ETF Advisors LLC increased its holdings in uniQure by 1.6% during the 2nd quarter. Main Management ETF Advisors LLC now owns 56,420 shares of the biotechnology company’s stock worth $786,000 after purchasing an additional 912 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in uniQure by 358.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company’s stock worth $99,000 after purchasing an additional 5,538 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new position in shares of uniQure in the 2nd quarter valued at approximately $117,000. Finally, Birchview Capital LP boosted its stake in shares of uniQure by 11.3% during the 2nd quarter. Birchview Capital LP now owns 98,697 shares of the biotechnology company’s stock valued at $1,376,000 after buying an additional 10,000 shares during the last quarter. 78.83% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. Leerink Partners dropped their price target on shares of uniQure from $68.00 to $60.00 and set an “outperform” rating for the company in a research note on Monday, November 10th. Wells Fargo & Company decreased their price objective on shares of uniQure from $80.00 to $60.00 and set an “overweight” rating for the company in a report on Wednesday, November 12th. Wall Street Zen downgraded shares of uniQure from a “hold” rating to a “sell” rating in a research report on Sunday, January 11th. William Blair reaffirmed a “market perform” rating on shares of uniQure in a research report on Tuesday, November 11th. Finally, Royal Bank Of Canada decreased their price target on uniQure from $65.00 to $45.00 and set an “outperform” rating for the company in a research note on Monday, November 3rd. Ten analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $60.82.

uniQure Trading Up 4.4%

uniQure stock opened at $22.69 on Friday. uniQure N.V. has a 1 year low of $7.76 and a 1 year high of $71.50. The firm’s 50-day moving average is $24.22 and its 200-day moving average is $27.94. The company has a debt-to-equity ratio of 0.23, a quick ratio of 7.12 and a current ratio of 7.12. The company has a market cap of $1.41 billion, a P/E ratio of -5.17 and a beta of 0.68.

uniQure (NASDAQ:QURE) last released its quarterly earnings data on Monday, November 10th. The biotechnology company reported ($1.38) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.53). uniQure had a negative return on equity of 373.73% and a negative net margin of 1,492.90%.The business had revenue of $3.70 million for the quarter, compared to analyst estimates of $4.46 million. On average, equities analysts expect that uniQure N.V. will post -3.75 earnings per share for the current year.

Insider Activity at uniQure

In other news, Director Jack Kaye sold 38,810 shares of the company’s stock in a transaction that occurred on Tuesday, November 4th. The stock was sold at an average price of $30.34, for a total transaction of $1,177,495.40. Following the completion of the transaction, the director directly owned 20,439 shares of the company’s stock, valued at approximately $620,119.26. This represents a 65.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Robert Gut sold 31,434 shares of the firm’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $27.26, for a total value of $856,890.84. Following the completion of the sale, the director directly owned 40,145 shares in the company, valued at approximately $1,094,352.70. This trade represents a 43.92% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 102,247 shares of company stock valued at $2,839,298 over the last ninety days. Corporate insiders own 4.79% of the company’s stock.

uniQure Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.